Investors Behind the Success of Zeblok

When it comes to drugs and medical treatments there is no ‘one-size fits all’. Patients vary greatly in their needs and responses. A treatment that is life-saving for one person might be ineffective or even harmful to another. This realization has led to the revolution of personalized medicine and drug design. It is helpful here that there is a certain degree of commonality among people. Much can be learned from partitioning the overall population of patients into subpopulations that share certain common features and attributes. However, identifying well-defined subpopulations remains to be a challenging endeavor. While there is nowadays no shortage in data that can be used to minutely characterize individual patients and the symptoms they exhibit, these detailed characterizations lead to vast and unwieldy feature spaces where patient subpopulations are rarely homogeneous and often difficult to separate. Furthermore, many of the features and attributes may not be important for a particular task but this is difficult to assess beforehand. Practitioners are often riddled with the problem of selecting the right features for a specific analysis problem. Unable to cope, feature selection reduces to a guessing game.

Investors on Board

Jon Doe

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

Jane Doe

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

James Doe

  • Grey LinkedIn Icon

I’m a paragraph. Double click me or click Edit Text, it's easy.

LINKS
ABOUT

Email: zeblok@zeblok.com

Tel: +1 (631) 223-8233

HQ Office:

1500 Stony Brook Road

Stony Brook, NY 11784

Office:

51 JFK Parkway

First Floor West

Short Hills, NJ 07078

    © 2020 Zeblok Computational, Inc.